Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab Monotherapy in Relapsed/Refractory Multiple Myeloma in India
NCT07881835Phase 4Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Feb 2029
01
Overview
A Phase 4 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07881835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881835.